Ivonescimab for Biliary Tract Cancer: China Trial Results and Questions Before Treatment Abroad
AI-generated editorial illustration of hepatobiliary specialist review; people and setting are fictional.
Quick Answer
If you are researching ivonescimab for bile duct cancer (cholangiocarcinoma) or gallbladder cancer in China, HARMONi-GI1 is evidence about first-line treatment for advanced disease. The China-led Phase III trial reported an overall-survival benefit for ivonescimab plus gemcitabine and cisplatin compared with durvalumab plus the same chemotherapy.
According to Akeso's October 25, 2026 trial release, median overall survival in HARMONi-GI1 was 14.9 months with ivonescimab plus chemotherapy and 12.1 months with durvalumab plus chemotherapy. The hazard ratio was 0.75. Median progression-free survival was 8.4 months versus 5.8 months, and the objective response rate was 53.8% versus 32.5%.
The results were presented at the ESMO Congress 2026 by a China-led research team. They are important Phase III evidence, but they do not mean this biliary-tract-cancer indication is already approved or available to every patient.
Key Takeaways
- HARMONi-GI1 compared ivonescimab plus chemotherapy directly with durvalumab plus chemotherapy in untreated advanced biliary tract cancer.
- The trial met its primary endpoint of overall survival and key secondary endpoints of progression-free survival and objective response rate.
- The study adds evidence that Chinese clinical teams are contributing to head-to-head global oncology research, not only early-stage drug development.
- Biliary tract cancer includes biologically different diseases, so tumour site and individual case details still matter.
- A positive trial result is not the same as regulatory approval, hospital availability or individual treatment suitability.
What Did HARMONi-GI1 Compare?
HARMONi-GI1 was a randomised, double-blind, multicentre Phase III trial in patients receiving first-line treatment for advanced biliary tract cancer. Both groups received gemcitabine and cisplatin. The investigational group received ivonescimab, while the comparison group received durvalumab.
Ivonescimab is a bispecific antibody designed to target PD-1 and VEGF in one molecule. Durvalumab plus chemotherapy is an established first-line immunotherapy approach for advanced biliary tract cancer, making this a clinically meaningful head-to-head comparison rather than a comparison with chemotherapy alone.
The study was presented at ESMO 2026 by Professor Jian Zhou of Zhongshan Hospital, Fudan University. Reporting by DXY described the study as a China-led effort involving patients with intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder cancer.
What Did the Phase III Results Show?
HARMONi-GI1: first-line advanced biliary tract cancer. Ivonescimab plus gemcitabine/cisplatin versus durvalumab plus the same chemotherapy. Data source: Akeso trial release, October 25, 2026.
| Trial measure | Ivonescimab + chemotherapy | Durvalumab + chemotherapy |
|---|---|---|
| Median overall survival | 14.9 months | 12.1 months |
| Median progression-free survival | 8.4 months | 5.8 months |
| Objective response rate | 53.8% | 32.5% |
| Serious adverse events | 43.4% | 43.7% |
The overall-survival hazard ratio was 0.75, corresponding to a 25% reduction in the risk of death during the study period. The progression-free-survival hazard ratio was 0.61.
These are trial-level results. They do not predict how long an individual patient will live or how a particular patient will respond.
Why Does This China-Led Result Matter?
Advanced biliary tract cancer remains difficult to treat, and a meaningful comparison against a current first-line immunotherapy regimen is more informative than a single-arm response report.
The result also reflects a broader change in China oncology. Chinese hospitals, investigators and drug developers are increasingly leading large registrational studies that test new treatments against active international standards. For international patients, that makes China a serious oncology market to monitor when standard pathways are limited or when a family wants a structured specialist review of emerging options.
For an overseas family, the first distinction is the treatment stage. A patient about to start first-line treatment has a different review question from someone whose cancer has progressed after several treatments. HARMONi-GI1 tested the former setting; it cannot answer a later-line treatment question on its own.
A useful China review should produce more than a reply that the drug exists. Ask which hepatobiliary and medical-oncology team will review the case, whether the proposed option addresses the actual tumour subtype and treatment stage, and what the next clinical review would clarify. Our cancer hospital selection checklist helps families compare those answers across institutions.
What Important Limits Should Readers Notice?
Biliary tract cancer is not one uniform disease. It includes intrahepatic and extrahepatic cholangiocarcinoma as well as gallbladder cancer. The DXY report noted that the clearest overall-survival signal was seen in the intrahepatic subgroup, while estimates in the smaller extrahepatic and gallbladder subgroups were less certain. Subgroup results should not be treated as separate proof of benefit.
Safety also remains part of the decision. Serious adverse-event rates were similar between groups in the reported analysis, but treatment selection still depends on organ function, performance status, bleeding risk, other medical conditions and clinician review.
Can International Patients Receive Ivonescimab for Biliary Tract Cancer in China?
The October 25, 2026 Akeso release reported that the first-line biliary tract cancer indication had been proposed for priority review in China. It was a trial-results announcement, rather than confirmation of approval for that indication. An approval for another cancer would not answer this disease-specific question.
Before planning treatment abroad, obtain current confirmation of the indication and proposed care route from the receiving team. Ask whether the hospital is offering an approved treatment, discussing a research protocol or recommending a different established option. These are different decisions with different review and follow-up requirements.
How Can CareNavigator Help?
CareNavigator helps international families reach and compare established Chinese hospitals and specialist teams with demonstrated hepatobiliary and medical-oncology experience. The comparison looks at case fit, relevant capability, practical access, total pathway cost and continuity with care at home.
We can clarify the clinical question, coordinate hospital communication and support the records needed for review. A useful outcome may be a clearer view of an established option, a research question or a reason to continue care locally. Our medical navigation approach explains how we turn hospital replies into practical next steps; clinical recommendations remain with qualified oncology teams.
Frequently Asked Questions
Does HARMONi-GI1 apply if chemotherapy has already stopped working?
HARMONi-GI1 studied first-line treatment for advanced biliary tract cancer. A patient whose disease has progressed after previous systemic treatment needs a separate specialist assessment of later-line options; this result alone does not establish what should come next.
Does a hospital offering ivonescimab mean it can treat my bile duct cancer?
Drug availability and a case-specific treatment recommendation are separate questions. Ask the receiving oncology team to confirm the exact cancer type, treatment setting, regulatory basis and proposed review route for your case.
How much would this treatment in China cost?
The HARMONi-GI1 result does not establish a treatment price for international patients. If a hospital identifies a relevant pathway, request an itemised estimate covering medicines, administration, tests, monitoring and hospital care, alongside travel, accommodation and follow-up costs.
Tell Us Your Situation
Are you comparing a first-line opinion or looking for another review after treatment has changed? Tell us your situation, including the diagnosis if known and the question your family needs answered. You can contact us before every record is ready; we can explain what a more detailed hospital review would need.
Source-Led Update Note
This article is a source-led rewrite based on reporting by DXY and primary trial information released for ESMO 2026. It is not a treatment recommendation. Trial results, regulatory status and hospital availability should be reviewed against current official information and the patient's case. Explore related reporting in China Advanced Treatment Updates.
Reporting and Trial Sources
- Reporting: DXY (丁香园), carried on Phoenix, October 26, 2026.
- Trial results: Akeso, company-issued results release, October 25, 2026.